Nintedanib

67 interactions 318 cited references
Also sold as: Ofev Ofev®
About Nintedanib

Nintedanib is used to treat idiopathic pulmonary fibrosis (IPF; scarring of the lungs with an unknown cause). It is also used to treat certain types of chronic fibrosing interstitial lung diseases (ILD; an ongoing disease in which there is increased scarring of the lungs). Nintedanib is also used to slow the rate of de… Read the full Nintedanib drug information page →

Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Aug 9, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Major

Nintedanib Abametapir Increased exposure of CYP3A4 substrate Details Nintedanib Apixaban Eliquis Increased risk of bleeding Details Nintedanib Capmatinib Tabrecta Increased P-gp substrate exposure and an increased risk of increased adverse reactions Details Nintedanib Dabigatran Pradaxa® Increased risk of bleeding Details Nintedanib Dabigatran Etexilate Increased risk of bleeding Details Nintedanib Dalteparin Injection Fragmin Increased risk of bleeding Details Nintedanib Enoxaparin Lovenox Increased risk of bleeding Details Nintedanib Enoxaparin Injection Lovenox Increased risk of bleeding Details Nintedanib Fondaparinux Arixtra Increased risk of bleeding Details Nintedanib Fondaparinux Injection Arixtra Increased risk of bleeding Details Nintedanib Heparin Increased risk of bleeding Details Nintedanib Heparin Injection Lipo-Hepin® Increased risk of bleeding Details Nintedanib Lenacapavir Injection Sunlenca Increased P-gp substrate exposure and an increased risk of P-gp substrate-related adverse reactions Details Nintedanib Lenacapavir Oral Sunlenca Increased P-gp substrate exposure and an increased risk of P-gp substrate-related adverse reactions Details Nintedanib Letermovir Injection Prevymis Increased CYP3A substrate exposure Details Nintedanib Acenocoumarol Increased risk of bleeding Details Nintedanib Apalutamide Erleada Reduced P-gp/CYP3A4 substrate exposure Details Nintedanib Ardeparin Increased risk of bleeding Details Nintedanib Argatroban Increased risk of bleeding Details Nintedanib Avacopan Tavneos Increased CYP3A4 substrate exposure Details Nintedanib Bemiparin Increased risk of bleeding Details Nintedanib Berotralstat Orladeyo Increased P-gp substrate exposure Details Nintedanib Bivalirudin Angiomax Increased risk of bleeding Details Nintedanib Carbamazepine Carbatrol Reduced nintedanib exposure Details Nintedanib Certoparin Increased risk of bleeding Details Nintedanib Clarithromycin Biaxin Increased exposure of CYP3A4 substrate and risk for toxicity Details Nintedanib Dalteparin Fragmin Increased risk of bleeding Details Nintedanib Danaparoid Increased risk of bleeding Details Nintedanib Desirudin Iprivask Increased risk of bleeding Details Nintedanib Drotrecogin Alfa Increased risk of bleeding Details Nintedanib Erythromycin Erythrocin Stearate Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse effects Details Nintedanib Fedratinib Inrebic Increased CYP3A4 substrate exposure Details Nintedanib Fexinidazole An increased CYP3A4 substrate exposure Details Nintedanib Fosphenytoin Cerebyx Reduced nintedanib exposure Details Nintedanib Itraconazole Sporanox Increased nintedanib exposure and an increased risk of nintedanib-related adverse effects Details Nintedanib Lenacapavir Sunlenca Increased P-gp substrate exposure and an increased risk of P-gp substrate-related adverse reactions Details Nintedanib Lepirudin Increased risk of bleeding Details Nintedanib Letermovir Prevymis Increased CYP3A substrate exposure Details Nintedanib Mifepristone Korlym Increased CYP3A4 substrate exposure Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.